Samuel Rosas1, Karim G Sabeh2, Leonard T Buller2, Tsun Yee Law3, Steven P Kalandiak2, Jonathan C Levy4. 1. Orthopedic Research Institute, Holy Cross Hospital, Fort Lauderdale, FL, USA; Department of Orthopedics and Rehabilitation, University of Miami, Miami, FL, USA. 2. Department of Orthopedics and Rehabilitation, University of Miami, Miami, FL, USA. 3. Orthopedic Research Institute, Holy Cross Hospital, Fort Lauderdale, FL, USA. 4. Orthopedic Research Institute, Holy Cross Hospital, Fort Lauderdale, FL, USA. Electronic address: Jonley123@yahoo.com.
Abstract
BACKGROUND: The purpose of this study was to evaluate the effect of common medical comorbidities on the reimbursements of different shoulder arthroplasty procedures. METHODS: We conducted a retrospective query of a single private payer insurance claims database using PearlDiver (Warsaw, IN, USA) from 2010 to 2014. Our search included the Current Procedural Terminology codes and International Classification of Diseases, Ninth Revision codes for total shoulder arthroplasty (TSA), hemiarthroplasty, and reverse shoulder arthroplasty (RSA). Medical comorbidities were also searched for through International Classification of Diseases codes. The comorbidities selected for analysis were obesity, morbid obesity, hypertension, smoking, diabetes mellitus, hyperlipidemia, atrial fibrillation, chronic obstructive pulmonary disease, cirrhosis, depression, and chronic kidney disease (excluding end-stage renal disease). The reimbursement charges of the day of surgery, 90-day global period, and 90-day period excluding the initial surgical day of each comorbidity were analyzed and compared. Statistical analysis was conducted through analyses of variance or Kruskal-Wallis test. RESULTS: Comorbidities did not have a significant effect on same-day reimbursements but instead caused a significant effect on the subsequent 89-day (interval) and 90-day reimbursements in the TSA and RSA cohorts. For TSA and RSA, the highest reimbursement costs during the 90-day period after surgery were seen with the diagnosis of hepatitis C, followed by atrial fibrillation and later chronic obstructive pulmonary disease. For hemiarthroplasty, the same was true in the following order: hepatitis C, cirrhosis, and atrial fibrillation. CONCLUSION: Shoulder arthroplasty reimbursements are significantly affected by comorbidities at time intervals following the initial surgical day.
BACKGROUND: The purpose of this study was to evaluate the effect of common medical comorbidities on the reimbursements of different shoulder arthroplasty procedures. METHODS: We conducted a retrospective query of a single private payer insurance claims database using PearlDiver (Warsaw, IN, USA) from 2010 to 2014. Our search included the Current Procedural Terminology codes and International Classification of Diseases, Ninth Revision codes for total shoulder arthroplasty (TSA), hemiarthroplasty, and reverse shoulder arthroplasty (RSA). Medical comorbidities were also searched for through International Classification of Diseases codes. The comorbidities selected for analysis were obesity, morbid obesity, hypertension, smoking, diabetes mellitus, hyperlipidemia, atrial fibrillation, chronic obstructive pulmonary disease, cirrhosis, depression, and chronic kidney disease (excluding end-stage renal disease). The reimbursement charges of the day of surgery, 90-day global period, and 90-day period excluding the initial surgical day of each comorbidity were analyzed and compared. Statistical analysis was conducted through analyses of variance or Kruskal-Wallis test. RESULTS: Comorbidities did not have a significant effect on same-day reimbursements but instead caused a significant effect on the subsequent 89-day (interval) and 90-day reimbursements in the TSA and RSA cohorts. For TSA and RSA, the highest reimbursement costs during the 90-day period after surgery were seen with the diagnosis of hepatitis C, followed by atrial fibrillation and later chronic obstructive pulmonary disease. For hemiarthroplasty, the same was true in the following order: hepatitis C, cirrhosis, and atrial fibrillation. CONCLUSION: Shoulder arthroplasty reimbursements are significantly affected by comorbidities at time intervals following the initial surgical day.
Authors: Vinay K Aggarwal; Eric H Tischler; Zachary D Post; Ian Kane; Fabio R Orozco; Alvin Ong Journal: J Bone Joint Surg Am Date: 2013-09-04 Impact factor: 5.284
Authors: Rolando Izquierdo; Ilya Voloshin; Sara Edwards; Michael Q Freehill; Walter Stanwood; J Michael Wiater; William C Watters; Michael J Goldberg; Michael Keith; Charles M Turkelson; Janet L Wies; Sara Anderson; Kevin Boyer; Laura Raymond; Patrick Sluka Journal: J Am Acad Orthop Surg Date: 2010-06 Impact factor: 3.020
Authors: Eric Q Wu; Howard G Birnbaum; Milena Mareva; Edward Tuttle; Adam R Castor; Warren Jackman; Jeremy Ruskin Journal: Curr Med Res Opin Date: 2005-10 Impact factor: 2.580
Authors: Nazeem A Virani; Christopher D Williams; Rachel Clark; John Polikandriotis; Katheryne L Downes; Mark A Frankle Journal: J Shoulder Elbow Surg Date: 2013-04-06 Impact factor: 3.019
Authors: Nazeem A Virani; Christopher D Williams; Rachel Clark; John Polikandriotis; Katheryne L Downes; Mark A Frankle Journal: J Shoulder Elbow Surg Date: 2013-03-17 Impact factor: 3.019
Authors: Leonard T Buller; Samuel Rosas; Karim G Sabeh; Martin W Roche; Alexander S McLawhorn; Wael K Barsoum Journal: J Arthroplasty Date: 2017-11-06 Impact factor: 4.757
Authors: Jay M Levin; John Wickman; Alexander L Lazarides; Daniel J Cunningham; Daniel E Goltz; Richard C Mather; Oke Anakwenze; Tally E Lassiter; Christopher S Klifto Journal: Clin Orthop Relat Res Date: 2022-01-11 Impact factor: 4.755